Parallel analysis of multiple genes on the DNA or RNA level is becoming more and more important, because cancer is identified as a disease that involves multiple genes. To study this cascade of genetic alterations, analysis on a single-gene level cannot be the final answer. Microarray analysis is state-of-the-art technology for fulfilling these scientific needs. The OSUCCC Microarray Shared Resource (MASR) was established as a """"""""developing"""""""" Shared Resource in 1998 initially serving investigators in the Molecular Biology and Cancer Genetics Program with genome wide expression analysis, and subsequently becoming one of the Shared Resources for the entire OSUCCC offering genome wide expression analysis using Affymetrix GeneChips. In September 2002, quantification of RNA integrity by capillary electrophoresis became available, and since September 2003, the MASR has offered validation of microarray results, via an array-based design of primers for real-time PCR. For projects utilizing any of these technologies, the MASR offers multiple services, including experimental design consultation, sample processing, hybridization, scanning, full statistical analysis and consultation, and validation of results. Newer services, such as custom arrays and SNPs are soon to be available. The MASR trains investigators to upload their results to Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) since this becomes mandatory for publication in many journals. The MASR website (www.dnaarrays.org) contains information about services, publications and downloadable protocols and order forms. The MASR offers timely, technical and professional expertise that promotes high quality science at a competitive price. To support OSUCCC researchers, several hundred RNA samples are processed each year for genome wide expression analysis. In addition, several hundred RNA samples are processed for integrity quantification. During 2003, the MASR worked with 30 investigators, 95% of who are CCC members affiliated with four CCC programs, and the amount of MASR service to these members increased 72% over the previous year. There are 42 current or pending grants from OSUCCC members that include utilization of the MASR. The OSUCCC has provided $2.1 M in Institutional support to establish and run the MASR as a """"""""developing"""""""" Shared Resource. We now request CCSG funding that will provide `30% of the total support for this important full Shared Resource over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743478
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$241,660
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications